News
Announcements
Spirit Scientific passes Japan PMDA audit for cell processing facilities, showcasing biofoundry™ strength
Spirit Scientific (7790) Becomes first company to receive PMDA certification for Platelet Lyophilization Processing Facilities On December 1, emerging biotech company Spirit Scientific (7790), listed on Taiwan's over-the-counter market, announced a major regulatory milestone. On November 20, the company received notification from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) under the Ministry of Health, Labour and Welfare (MHLW) confirming the successful completion of the overseas specified cell processing facility inspection. This achievement grants Spirit Scientific the Specified Cell Processed Products Manufacturing Certification from the Japanese MHLW, making it the first Taiwanese
Spirit Scientific BioTech Wins Ministry of Economic Affairs'”Startup Award,” Innovative Operating Strategy Recognized
Nov 19, 2025, The 24th "Startup Award" ceremony, hosted by the Ministry of Economic Affairs (MOEA), was grandly held yesterday at the NTUH International Convention Center. Spirit Scientific BioTech (7790), which focuses on precision regenerative medicine, was honored with the "Startup Award" in the Technology Industry category, demonstrating recognition for its technical innovation and outstanding operating performance.Spirit Scientific BioTech stated that it holds the core technology of Biological Material Lyophilization Technology (BMLT ®) and has developed an innovative service model: the Biofoundry™ Diamond-Grade Lyophilization Preparation Service. This model provides standardized and
Spirit Scientific biotech featured in famous media, Global Bio & Investment, Vol. 128
Spirit Scientific biotech featured in famous media, Global Bio & Investment, Vol. 128 Source: https://news.gbimonthly.com/tw/magazine/article_show.php?num=78723
Spirit Scientific won 2 special prizes in Golden Peak Award, and showcases hair growth innovations at AMWC Asia-TDAC 2025
Spirit Scientific (7790) showcased its high-concentration PLT services and new platelet-derived cellular signal factors lyophilization services at the 2025 Taiwan Dermatological Association Spring Academic Conference (AMWC Asia-TDAC 2025) held in Taipei. The company also announced its recent receipt of the prestigious "Golden Peak Award," earning "Top Ten Outstanding Products" and "Top Ten Outstanding Entrepreneurship Models." The conference, co-organized by the Taiwan Dermatological Association (TDA) and the Taiwan Society for Dermatologic and Cosmetic Surgery (TSDAS), is a major event in East Asia focusing on cutting-edge advancements in cosmetic medicine, dermatology, and
Spirit Scientific biotech won double prizes at Golden Peak Awards
Spirit Scientific biotech has been honored with two prestigious awards at the Golden Peak Awards ceremony held on the evening of April 25th. Competing against over 500 companies, Spirit Scientific's innovative high-concentration platelet lyophilized preparation service earned them the "Top Ten Outstanding Products" award. Furthermore, their Founder and Chairman, Lin Daolong, was recognized with the "Top Ten Outstanding Entrepreneurial Role Models" award. This marks a significant achievement, securing a double win for the company. The Golden Peak Awards, organized by the Chinese Management Association, is a benchmark award for innovative
Achieving healthy skin for acne-prone and sensitive skin: Dr. Wu Min-Hsiu of Yueh Chen aesthetic clinic shares insights on a holistic approach to aesthetic medicine
Dr. Wu Min-Hsiu from Yueh Chen Aesthetic Clinic emphasizes that true beauty stems from skin health, not just cosmetic procedures. While treatments like lasers and light therapies offer quick results for issues like acne scars, hyperpigmentation, and fine lines, they should complement, not replace, a consistent daily skincare routine including gentle cleansing, moisturizing, sun protection, and healthy lifestyle habits. Dr. Wu warns against over-reliance on frequent aesthetic treatments without proper post-procedure care, which can lead to weakened, sensitive skin prone to redness and irritation. He advocates for a personalized approach,
Spirit Scientific biotech showcases innovative long-lasting repair PLTgel for rehabilitation and sports medicine
Spirit Scientific (7790) presented its "PLTgel", a gel-form, high-concentration platelet lyophilized (PLT) slow-release preparation service, at the 2025 Taiwan Association of Rehabilitation Medicine Annual Meeting. This innovative solution targets the clinical needs of rehabilitation and sports medicine by offering a novel, long-acting repair option. Unlike liquid PLT or traditional Platelet-Rich Plasma (PRP), PLTgel's gel-like consistency is better suited for large-area soft tissue injuries, including cartilage, muscle, tendon, and ligament tears or defects, as well as degenerative arthritis. Physicians at the conference highlighted its enhanced adhesion to the affected area and
Taiwanese biotech Spirit Scientific expands into Japan with advanced regenerative medicine technology
Spirit Scientific, a regenerative medicine startup from New Taipei City, Taiwan, officially entered the Japanese market in 2023. The company focuses on Platelet-Rich Plasma (PRP) therapy, leveraging its innovative platelet lyophilization technology for long-term preservation as a key competitive advantage. Their goal is to popularize and advance the clinical application of this treatment. Strategic Expansion and Growth Spirit Scientific chose Japan as its first international market due to its well-established regulatory framework for regenerative medicine, which provides a supportive environment for clinical and commercial applications. The company also recognized Japan's
Spirit Scientific launches platelet-derived cellular signal factors lyophilization services, driving new momentum in biotechnology
Spirit Scientific (7790), a Taiwanese regenerative medicine startup, has launched its autologous platelet-derived cellular signal factors lyophilization services. This innovation follows the recent legislative approval of the Regenerative Medicine Law and Regulations in Taiwan, aligning with the "Healthy Taiwan" policy and boosting the competitiveness of the biotech and medical industry. Cellular signal factors, nanoscale vesicles secreted by cells, act as intercellular messengers containing proteins, mRNA, and other biomolecules. They play crucial roles in tissue repair, immune regulation, and more, offering significant potential in diagnostics and therapeutics. Leveraging nearly a decade
Announcement: Transition to new corporate image and coexistence of old and new packaging
Dear Valued Customers and Partners, Thank you for your continuous support and trust. To enhance our brand image and service quality, we have been updating our corporate image and logo this year, reflecting our spirit of innovation and pursuit of excellence. While embracing this brand upgrade, we are also deeply committed to environmental responsibility, energy conservation, and carbon reduction. As part of this commitment, our product packaging and promotional materials will be phased out gradually. To prevent the waste of resources associated with a one-time disposal of old packaging,
【Spirit Scientific】攜最新專利血小板療法進軍日本市場，開闢再生醫學新路徑
Spirit Scientific選擇進入日本市場作為其第一個海外市場！ 日本子公司正為市場拓展做準備，並在東京設立有明實驗室。 台灣凍乾血小板製造領導品牌Spirit Scientific首次於Medical Japan Tokyo登場， Medical Japan Tokyo 是一個大型醫療相關展會，有超過600家參展商參加，於 10 月 9 日至 11 日在千葉縣 幕張舉辦，為期三天。 思必瑞特生技將重點展示其專利且引人注目的血小板冷凍乾燥技術，該技術利用科學方法將富含生長因子的血小板修復能力最大化。 思必瑞特生技創辦人暨董事長林道隆強調，思必瑞特生技的血小板冷凍乾燥技術PLT（Platelet Lyophilized Technology）的商業模式在台灣已經累積了超過3萬個實際案例。 為了準備在日本市場的製造和分銷，我們正在東京有明建立一個內部設計的實驗室設施，預計今年底完工。 我們的PLT凍晶將能為日本民眾提供安全、優質的再生醫學療法新選擇。未來，我們將與日本醫療機構緊密合作，目標為進入日本再生醫學千億日圓的血小板萃取相關市場。 Spirit Scientific 利用 PLT 技術解決 PRP 挑戰 傳統的PRP（高濃度血小板血漿）療法已有50多年的歷史，血小板中含有的各種生長因子也被證實具有促進血管生成和組織修復的潛力。然而，實際的治療效果也存在差異。若要確保療效，每次治療時都需控制血小板顆粒計數和生長因子濃度，但傳統PRP療法存在的問題是血小板萃取情況取決於現場工作人員的能力，而且容易受到患者身體狀況的影響。 為了解決這些 PRP 問題，思必瑞特生技Spirit Scientific開發了專利血小板冷凍乾燥技術 (PLT)。該技術使用標準化流程生產「固定劑量」的冷凍乾燥血小板。除了確保每瓶中有 10 億個血小板外，亦提供生長因子濃度報告。這使得醫生可以根據治療情況調整“最佳劑量”，從而顯著提高治療品質和效果。 Spirit Scientific總部位於台灣，將基於此專利製程開發完整的冷凍乾燥血小板生長因子生產，包括數位化的血袋收檢服務和溫控運輸。我們在Class 10,000等級，同GTP標準的無塵實驗室中進行PLT冷凍乾燥的專利製造方法，最後進行Gamma-ray輻射滅菌和真空包裝，確保產品安全無菌。 經藥物穩定性測試驗證，Spirit Scientific 的 PLT 冷凍乾燥血小板生長因子在室溫下的保存期為 3 年。其穩定性和安全性不僅大大超過傳統的PRP，而且優於最近開發的冷凍血小板因子濃縮物（PRP-FD）。 目前，思必瑞特生技技已在台灣、日本、美國、中國等地取得11項專利，另有9項跨國專利正在審查中。 PLT 凍晶在骨科、復健科、美容醫學專科、皮膚科、婦產科和泌尿科等廣泛臨床領域的積極應用潛力已得到證實。 Spirit Scientific選擇並進入日本市場作為其第一個海外市場 Spirit Scientific的業績記錄和未來前景在其總公司所在地-台灣已得到了認可，並於2021年獲得了行政院國家發展基金和達盈領投(Darwin Ventures)的A輪融資，籌集了約1億美元(約4.6億日圓）的資金。 於2023年，我們在日本設立了子公司以進入日本市場，並開始籌備在東京江東區有明開設全新實驗室。除此之外，我們也獲得了日本最大的獨立創投公司JAFCO的投資，並一直在穩步準備在日本的擴張。 目前，我們在日本的實驗室已經基本完成，並計劃申請日本醫藥品醫療機器綜合機構(Pharmaceuticals and Medical Devices Agency, PMDA)以及人體細胞組織優良操作規範(Good Tissue Practice, GTP)的認證。期待未來發展專業代工(OEM)服務，並透過與日本醫療機構的合作夥伴來提供我們的服務。 思必瑞特生技創辦人兼董事長-林道隆強調，我們正在擴大生物鑄造(Biofoundry)業務，並專注於生物材料冷凍乾燥製造工藝。其中 Spirit Scientific 擁有出色的技術，為更多尋求再生醫學的患者提供安全、優質的產品，並提供高品質且值得信賴的精準化醫療解決方案。 日本思必瑞特生技株式會社 https://sslabs.co.jp/ 文: PR TIMES Japan / 譯: 思必瑞特生技 行銷部
思必瑞特生技 (股票代號：7790) IPO公開發行公告
思必瑞特生技 (股票代號：7790) 公開發行成功 思必瑞特生技股份有限公司於今（9/25）日欣然宣布，正式進行IPO公開發行，股票代號為7790，並將持續朝向興櫃目標邁進。這一重要里程碑，不僅標誌著思必瑞特生技在資本市場的成功進駐，也代表公司未來將有更多的資源與動力來推動創新研發，持續為生技產業貢獻力量。 在此特別感謝所有支持思必瑞特生技的合作夥伴、投資者及全體同仁，感謝各位一路以來的信任與支持。未來我們將繼續秉持「掌握科學，成就美好」的核心理念，以科學精神，探索未來醫療樣態及未被滿足的醫療需求。專注於開發及優化生物材料凍晶技術的同時，也持續提供精準化血小板凍晶製備相關服務，並積極推廣生物鑄造廠Biofoundry理念實踐，以提升再生醫學照護標準，並以改善全人類的生活品質為目標。 思必瑞特生技 謹致 2024年9月25日
